Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants

Objective: Canagliflozin, a sodium-glucose co-transporter 2 inhibitor, approved for the treatment of type-2 diabetes mellitus (T2DM), is metabolized by uridine diphosphate-glucuronosyltransferases (UGT) 1A9 and UGT2B4, and is a substrate of P-glycoprotein (P-gp). Canagliflozin exposures may be affec...

Descripción completa

Detalles Bibliográficos
Autores principales: Devineni, Damayanthi, Vaccaro, Nicole, Murphy, Joe, Curtin, Christopher, Mamidi, Rao N.V.S., Weiner, Sveta, Wang, Shean-Sheng, Ariyawansa, Jay, Stieltjes, Hans, Wajs, Ewa, Di Prospero, Nicholas A., Rothenberg, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558628/
https://www.ncbi.nlm.nih.gov/pubmed/25407255
http://dx.doi.org/10.5414/CP202158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558628/
https://www.ncbi.nlm.nih.gov/pubmed/25407255
http://dx.doi.org/10.5414/CP202158

Ejemplares similares